Humana, Centene And Medicare Coverage Will Increase Screening Access

Published
27 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$62.97
27.6% undervalued intrinsic discount
15 Aug
US$45.60
Loading
1Y
-22.4%
7D
11.2%

Author's Valuation

US$63.0

27.6% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on08 Aug 25
Fair value Decreased 2.52%

Despite a slight rise in Exact Sciences’ future P/E ratio and a modest decline in its net profit margin, the consensus analyst price target remains unchanged at $64.60. What's in the News Exact Sciences raised full-year 2025 revenue guidance to $3.13–$3.17 billion, up from previous estimates of $3.07–$3.12 billion, reflecting strong business momentum (Key Developments, 2025-08-06).

Shared on01 May 25
Fair value Decreased 5.75%